Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ScinoPharm Taiwan

TSEC:1789
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1789
TSEC
NT$21B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • ScinoPharm Taiwan has significant price volatility in the past 3 months.
1789 Share Price and Events
7 Day Returns
6.5%
TSEC:1789
3.1%
TW Pharmaceuticals
-0.2%
TW Market
1 Year Returns
3.1%
TSEC:1789
-22.5%
TW Pharmaceuticals
-10.7%
TW Market
1789 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ScinoPharm Taiwan (1789) 6.5% -12.9% 3.8% 3.1% -35% -40%
TW Pharmaceuticals 3.1% -16.9% -19.8% -22.5% -29.8% -30.6%
TW Market -0.2% -15.3% -20.2% -10.7% -4.1% -0.7%
1 Year Return vs Industry and Market
  • 1789 outperformed the Pharmaceuticals industry which returned -22.5% over the past year.
  • 1789 outperformed the Market in Taiwan, Province of China which returned -10.7% over the past year.
Price Volatility
1789
Industry
5yr Volatility vs Market

1789 Value

 Is ScinoPharm Taiwan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ScinoPharm Taiwan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ScinoPharm Taiwan.

TSEC:1789 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year TW Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSEC:1789
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.2%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 20%) (3.93%))
0.804
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.71% + (0.804 * 6.21%)
5.7%

Discounted Cash Flow Calculation for TSEC:1789 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ScinoPharm Taiwan is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

TSEC:1789 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 5.7%)
2020 412.00 Analyst x1 389.77
2021 658.00 Analyst x1 588.92
2022 575.03 Est @ -12.61% 486.89
2023 525.50 Est @ -8.61% 420.95
2024 494.94 Est @ -5.82% 375.07
2025 475.84 Est @ -3.86% 341.15
2026 464.00 Est @ -2.49% 314.71
2027 456.91 Est @ -1.53% 293.18
2028 452.99 Est @ -0.86% 274.99
2029 451.24 Est @ -0.39% 259.15
Present value of next 10 years cash flows NT$3,744.00
TSEC:1789 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$451.24 × (1 + 0.71%) ÷ (5.7% – 0.71%)
NT$9,102.16
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$9,102.16 ÷ (1 + 5.7%)10
NT$5,227.38
TSEC:1789 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$3,744.00 + NT$5,227.38
NT$8,971.38
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$8,971.38 / 790.74
NT$11.35
TSEC:1789 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$11.35
Current discount Discount to share price of NT$27.00
= -1 x (NT$27.00 - NT$11.35) / NT$11.35
-138%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of ScinoPharm Taiwan is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ScinoPharm Taiwan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ScinoPharm Taiwan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSEC:1789 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in TWD NT$0.27
TSEC:1789 Share Price ** TSEC (2020-04-01) in TWD NT$27
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 25 Publicly-Listed Pharmaceuticals Companies 19.14x
Taiwan, Province of China Market PE Ratio Median Figure of 1,472 Publicly-Listed Companies 13.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ScinoPharm Taiwan.

TSEC:1789 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSEC:1789 Share Price ÷ EPS (both in TWD)

= 27 ÷ 0.27

100x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ScinoPharm Taiwan is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • ScinoPharm Taiwan is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does ScinoPharm Taiwan's expected growth come at a high price?
Raw Data
TSEC:1789 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 100x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
44.3%per year
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.87x
Taiwan, Province of China Market PEG Ratio Median Figure of 183 Publicly-Listed Companies 1.08x

*Line of best fit is calculated by linear regression .

TSEC:1789 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 100x ÷ 44.3%

2.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ScinoPharm Taiwan is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on ScinoPharm Taiwan's assets?
Raw Data
TSEC:1789 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in TWD NT$12.25
TSEC:1789 Share Price * TSEC (2020-04-01) in TWD NT$27
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 1.82x
Taiwan, Province of China Market PB Ratio Median Figure of 1,961 Publicly-Listed Companies 1.17x
TSEC:1789 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSEC:1789 Share Price ÷ Book Value per Share (both in TWD)

= 27 ÷ 12.25

2.2x

* Primary Listing of ScinoPharm Taiwan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ScinoPharm Taiwan is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess ScinoPharm Taiwan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. ScinoPharm Taiwan has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1789 Future Performance

 How is ScinoPharm Taiwan expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ScinoPharm Taiwan expected to grow at an attractive rate?
  • ScinoPharm Taiwan's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • ScinoPharm Taiwan's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • ScinoPharm Taiwan's revenue growth is expected to exceed the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
TSEC:1789 Future Growth Rates Data Sources
Data Point Source Value (per year)
TSEC:1789 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 44.3%
TSEC:1789 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 10.9%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 38.9%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 14.4%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSEC:1789 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSEC:1789 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 3,712 908 545 1
2020-12-31 2,754 662 169 1
2020-04-04
TSEC:1789 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-12-31 2,893 789 217
2019-09-30 2,933 992 262
2019-06-30 3,067 1,306 312
2019-03-31 3,435 1,352 386
2018-12-31 3,524 1,232 443
2018-09-30 3,560 1,059 410
2018-06-30 3,591 990 434
2018-03-31 3,458 964 388
2017-12-31 3,516 972 422
2017-09-30 3,624 1,324 508
2017-06-30 3,767 1,191 567
2017-03-31 3,929 1,306 657

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ScinoPharm Taiwan's earnings are expected to grow significantly at over 20% yearly.
  • ScinoPharm Taiwan's revenue is expected to grow by 10.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSEC:1789 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from ScinoPharm Taiwan Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSEC:1789 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.69 0.69 0.69 1.00
2020-12-31 0.21 0.21 0.21 1.00
2020-04-04
TSEC:1789 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-12-31 0.27
2019-09-30 0.33
2019-06-30 0.39
2019-03-31 0.49
2018-12-31 0.56
2018-09-30 0.52
2018-06-30 0.55
2018-03-31 0.49
2017-12-31 0.53
2017-09-30 0.64
2017-06-30 0.72
2017-03-31 0.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ScinoPharm Taiwan is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess ScinoPharm Taiwan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ScinoPharm Taiwan has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1789 Past Performance

  How has ScinoPharm Taiwan performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ScinoPharm Taiwan's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ScinoPharm Taiwan's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • ScinoPharm Taiwan's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • ScinoPharm Taiwan's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
ScinoPharm Taiwan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ScinoPharm Taiwan Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSEC:1789 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2,892.78 216.66 670.96 238.37
2019-09-30 2,932.90 261.58 681.41 296.29
2019-06-30 3,066.99 311.98 671.67 263.06
2019-03-31 3,435.02 385.92 675.16 308.17
2018-12-31 3,524.26 442.98 670.89 313.21
2018-09-30 3,559.61 410.02 655.07 284.58
2018-06-30 3,590.73 434.42 659.66 317.20
2018-03-31 3,458.28 387.76 649.73 305.45
2017-12-31 3,516.48 422.37 676.92 314.28
2017-09-30 3,623.96 508.37 683.76 294.01
2017-06-30 3,766.76 566.91 671.88 282.80
2017-03-31 3,928.65 656.90 674.97 275.95
2016-12-31 4,030.92 658.69 658.11 279.58
2016-09-30 4,058.54 707.10 649.47 304.97
2016-06-30 4,049.86 736.30 647.03 309.26
2016-03-31 3,997.91 694.10 644.02 315.49
2015-12-31 3,955.21 634.97 602.74 324.21
2015-09-30 3,775.41 444.59 589.47 330.71
2015-06-30 3,794.95 371.23 590.55 354.78
2015-03-31 3,979.66 431.59 594.94 399.01
2014-12-31 4,097.84 484.14 625.24 415.89
2014-09-30 4,571.84 744.00 693.84 454.89
2014-06-30 4,809.16 875.11 698.15 450.83
2014-03-31 4,999.87 1,088.63 712.45 416.65
2013-12-31 5,088.25 1,273.40 727.16 417.88
2013-09-30 5,168.26 1,431.21 765.90 347.02
2013-06-30 5,212.57 1,504.20 775.82 333.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • ScinoPharm Taiwan has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • ScinoPharm Taiwan used its assets less efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • ScinoPharm Taiwan's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess ScinoPharm Taiwan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ScinoPharm Taiwan has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1789 Health

 How is ScinoPharm Taiwan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ScinoPharm Taiwan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ScinoPharm Taiwan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ScinoPharm Taiwan's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ScinoPharm Taiwan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 23.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ScinoPharm Taiwan Company Filings, last reported 3 months ago.

TSEC:1789 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 10,259.94 234.00 3,480.12
2019-09-30 10,309.59 270.74 3,403.99
2019-06-30 10,421.06 1,367.59 4,714.67
2019-03-31 10,818.68 1,388.30 4,716.50
2018-12-31 10,539.03 1,411.79 4,381.95
2018-09-30 10,591.42 1,664.30 4,311.64
2018-06-30 10,530.13 1,779.53 4,292.40
2018-03-31 10,717.25 1,744.12 4,213.35
2017-12-31 10,417.23 1,691.93 3,910.79
2017-09-30 10,351.29 1,888.68 3,950.34
2017-06-30 10,231.45 1,788.71 3,720.97
2017-03-31 10,358.24 1,693.48 3,718.47
2016-12-31 10,227.79 1,785.70 3,707.15
2016-09-30 10,094.54 1,767.14 3,186.54
2016-06-30 9,957.78 1,716.23 3,087.43
2016-03-31 10,027.09 1,686.25 2,986.81
2015-12-31 9,856.99 1,702.31 2,619.91
2015-09-30 9,700.51 1,679.23 2,377.67
2015-06-30 9,450.23 1,489.74 2,409.77
2015-03-31 9,476.53 1,363.18 2,009.37
2014-12-31 9,380.27 1,277.48 1,927.60
2014-09-30 9,325.24 1,123.19 1,303.05
2014-06-30 9,159.61 1,006.44 2,186.17
2014-03-31 9,807.54 1,070.16 2,792.77
2013-12-31 9,643.25 689.79 2,289.43
2013-09-30 9,347.95 742.83 2,735.66
2013-06-30 9,109.47 755.04 3,379.00
  • ScinoPharm Taiwan's level of debt (2.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (13.6% vs 2.3% today).
  • Debt is well covered by operating cash flow (337.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.8x coverage).
X
Financial health checks
We assess ScinoPharm Taiwan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ScinoPharm Taiwan has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1789 Dividends

 What is ScinoPharm Taiwan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1%
Current annual income from ScinoPharm Taiwan dividends. Estimated to be 2.09% next year.
If you bought NT$2,000 of ScinoPharm Taiwan shares you are expected to receive NT$20 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • ScinoPharm Taiwan's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (3.26%).
  • ScinoPharm Taiwan's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (6.99%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSEC:1789 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 3.2%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1329 Stocks 4.6%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.8%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 3.3%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSEC:1789 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.56 1.00
2020-12-31 0.57 1.00
2020-04-04
TSEC:1789 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2020-03-27 0.270 1.033
2020-03-19 0.270 1.120
2019-06-27 0.490 1.923
2018-07-05 0.480 1.785
2017-03-30 0.289 0.817
2016-07-20 0.277 0.706
2015-07-13 0.178 0.440
2014-07-17 1.026 2.229
2013-03-22 0.986 1.466
2012-03-27 0.798 1.655
2011-10-27 0.080 0.214
2011-08-29 0.080 0.195
2011-04-28 0.080 0.163

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ScinoPharm Taiwan is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are stable.
  • ScinoPharm Taiwan is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of ScinoPharm Taiwan's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of ScinoPharm Taiwan's dividends as it is not paying a notable one for Taiwan, Province of China.
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.2x coverage).
X
Income/ dividend checks
We assess ScinoPharm Taiwan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ScinoPharm Taiwan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ScinoPharm Taiwan has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1789 Management

 What is the CEO of ScinoPharm Taiwan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Su
AGE 62
TENURE AS CEO 1.8 years
CEO Bio

Mr. Tsung-Ming Su, also known as Tony, MBA has been President and Chief Executive Officer at ScinoPharm Taiwan, Ltd. July 05, 2018. Mr. Su serves as President of President International Development Corp., President Life Sciences Co., Ltd., President Property Corporation. Mr. Su has been Senior Vice President of Uni-President Enterprises Corporation since May 1, 2008. He served as Director of Finance Group at Uni-President Enterprises Corporation from August 01, 2002 to July 01, 2017. He serves as Vice President and Chief Financial Officer of Uni-President Group. He serves as Supervisor of Grand Bills Finance Corp., Nanlien International Corp., Presco Netmarketing Inc., PresidentTokyo Corp. and President Tokyo Auto Leasing Corp. He served as Vice President of Uni-President Enterprises Corp., since April 16, 2007 and also served as its Assistant Vice President from August 1, 2000 to April 16, 2007. He has over 22 years of experience in banking and financial management. Prior to joining Uni-President Group in August 2000, he served as Vice-President of the Taipei branch of Citibank. He was the financial specialist of Seibu Department Store in Tokyo in 1988 and the senior specialist of Nortel Networks Asia/Pacific in Tokyo in 1990. He has been Representative Director of President Chain Store Corp. since February 14, 2008. He serves as a Director of Grand Bills Finance Corp. and has been Representative Director of ScinoPharm Taiwan, Ltd. since July 6, 2010. He has been a Non Executive Director of Uni-President China Holdings Ltd., since August 8, 2007. Mr. Su holds an MBA from the Iowa State University.

CEO Compensation
  • Insufficient data for Tony to compare compensation growth.
  • Insufficient data for Tony to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the ScinoPharm Taiwan management team in years:

6.3
Average Tenure
  • The average tenure for the ScinoPharm Taiwan management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Alex Lo

TITLE
Chairman & General Chief Strategy Officer
AGE
62
TENURE
2.7 yrs

Tony Su

TITLE
President
AGE
62
TENURE
1.8 yrs

Chih-Ching Hsu

TITLE
Senior Director of Finance
TENURE
1.7 yrs

Freon Chen

TITLE
Vice President of Operations
TENURE
12.7 yrs

Carrie Lin

TITLE
Senior Director of Accounting

Susan Lu

TITLE
Vice President of Administration & Spokesperson

Portia Lin

TITLE
VP of Marketing & Sales and Chief Strategy Officer
TENURE
9.8 yrs

Jessie Wang

TITLE
Director of Human Resources & Administration
TENURE
10.6 yrs

Gloria Chang

TITLE
VP of Injectable Business Division & CSO
Board of Directors Tenure

Average tenure of the ScinoPharm Taiwan board of directors in years:

4.8
Average Tenure
  • The tenure for the ScinoPharm Taiwan board of directors is about average.
Board of Directors

Tony Su

TITLE
President
AGE
62
TENURE
9.8 yrs

Wei-te Ho

TITLE
Independent Director
TENURE
7.8 yrs

Alex Lo

TITLE
Chairman & General Chief Strategy Officer
AGE
62
TENURE
2.7 yrs

Shiow-Ling Kao

TITLE
Representative Director
TENURE
9.8 yrs

Chiou-Ru Shih

TITLE
Representative Director
TENURE
9.8 yrs

Kun-Shun Tsai

TITLE
Representative Director
TENURE
4.8 yrs

Tsung-Pin Wu

TITLE
Representative Director
TENURE
4.8 yrs

Kuo-his Wang

TITLE
Director
TENURE
4.3 yrs

Po-Ming Hou

TITLE
Representative Director
TENURE
3.4 yrs

Jia-Horng Guo

TITLE
Representative Director
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess ScinoPharm Taiwan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ScinoPharm Taiwan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1789 News

Simply Wall St News

1789 Company Info

Description

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and brand company outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, exploratory process research, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures Western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. The company has a strategic partnership with Baxter International Inc. to develop, manufacture, and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and common side effects of chemotherapy. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan.

Details
Name: ScinoPharm Taiwan, Ltd.
1789
Exchange: TSEC
Founded: 1997
NT$21,349,958,994
790,739,222
Website: http://www.scinopharm.com
Address: ScinoPharm Taiwan, Ltd.
No. 1, Nan-Ke 8th Road,
Southern Taiwan Science Park,
Tainan,
74144,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSEC 1789 Common Stock Taiwan Stock Exchange TW TWD 29. Oct 2010
Number of employees
Current staff
Staff numbers
0
ScinoPharm Taiwan employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 18:00
End of day share price update: 2020/04/01 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/19
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.